8:00-8:30 |
Registration and Coffee |
8:30-9:15 |
State of the Neurotechnology Industry: 2020
James Cavuoto, Editor and Publisher, Neurotech Reports
Neurotech Business Report Editor James Cavuoto provides his insights and observations on the state of the neurotechnology industry. He surveys changes in the competitive landscape that have occured over the years, the most significant events of the last year, and challenges confronting the industry in years ahead. |
9:15-10:00 |
Keynote Address
Konstantinos Alataris, Ph.D., Founder, Nevro Corp. |
10:00-10:30 |
Refreshment Break |
10:30-11:15 |
Surviving the Times: Obtaining Funding in the Pandemic Era
Jennifer French, Senior Contributing Editor, Neurotech Reports, Moderator
Trish Costello, Founder & CEO, Portfolia
Diana Saraceni, General Partner, Panakes SGR
Faz Bashi, Life Science Syndication Chair, Angel Capital Association
Emily Caporello, Ph.D., Director, NINDS Small Business, Programs, National Institutes of Health
There are many opportunities for neurotech startups to obtain financing despite the economic downturn caused by the coronavirus pandemic. In this session, panelists will discuss the state of affairs in the investment community and the likely outlook for the years ahead, |
11:15-12:00 |
Succeeding from Failure: Lessons Learned from Previous Neurotech Failures
James Cavuoto, Editor, Neurotech Reports, Moderator
Victor Pikov, Ph.D., President and CEO, Medipace
Jeremy Koff, Senior Consulting Editor, Neurotech Reports
Tim Marjenin, Vice President, Neurology Regulatory Affairs, MCRA LLC
In this session, we'll examine several recent examples of neurotechnology startups or product launches that proved unsuccessful and review what lessons new startups can draw from them. |
12:00-1:30 |
Luncheon, Sponsored by Cirtec Medical |
1:30-3:00 |
Neurotechnology Entrepreneur Panel
James Cavuoto, Editor, Neurotech Reports, Moderator
Karen Crow, CEO, NeuroGeneces
Robert Rennaker, Ph.D., Co-founder and CEO, X-Nerve
Eric Chanie, Entrepreneur in Residence, Wyss Center/Epios
Ian Halpern, CEO and Co-founder, Modular Bionics, Inc.
Andreas Forsland, CEO, Cognixion
This session features presentations from CEOs and executives of several neurotechnology start-up firms and more established technology ventures. Each executive will present an overview of their firm's technology and markets. |
3:00-3:30 |
Refreshment Break |
3:30-4:15 |
SCS Excess: The New Landscape in Spinal Cord Stimulation
Jeremy Koff, Senior Contributing Editor, Neurotech Reports, Moderator
Victor Krauthamer, Ph.D., Adjunct Professor, George Washington University
Josh Boggs, Ph.D., Senior Vice President, SPR Therapeutics
Rosana Esteller, Senior R&D Manager, Neuromodulation, Boston Scientific
Michelle Byers-Robson, Director of Education, American Society of Pain & Neuroscience
Medtronic's new DTM platform could be a game changer in the SCS market. But Boston Scientific, Abbott, Nevro, Saluda, and several other upstarts could also have a major impact. In this session, clinicians and industry experts will discuss the current SCS landscape. |
4:15-5:00 |
Getting Off the Bench: Neurotech Research Labs Spur New Product Directions
Jo Jo Platt, Contributing Editor, Neurotech Reports, Moderator
Shadi Dayeh, Ph.D., Professor, UC San Diego
Andrew Cornwell, Ph.D., Director of Industrial and Strategic Collaborations, Cleveland FES Center
Hubert Lim, Ph.D., Associate Professor of Biomedical Engineering, University of Minnesota
In this session, we'll take a look at some of the leading research institutions involved with neurotechnology and explore the commercial relationships that have emerged.
|
5:00-7:00 |
Cocktail Reception, Sponsored by MST
|
|
|
8:00:8:30 |
Registration and Coffee |
8:30-9:15 |
Facing the Public: An Editorial Perspective
James Cavuoto, Editor and Publisher, Neurotech Reports, Moderator
Jennifer French, Senior Contributing Editor, Neurotech Reports
Jeremy Koff, Senior Consulting Editor, Neurotech Reports
Jo Jo Platt, Contributing Editor, Neurotech Reports
In this session, Neurotech Reports team of editors will offer their views on recent controversies facing the neuromodulation industry, including ethical concerns, dealing with bad press, and legislative and regulatory developments.
|
9:15-9:30 |
Entrepreneur Presentation
Lloyd Diamond, CEO, Pixium Vision
|
9:30-10:00 |
Keynote Address
Bryan Johnson, CEO, Kernel
|
10:00-10:30 |
Coffee Break
|
10:30-11:15 |
Repelling the Invasion: Surface Stimulation Makes a Comeback
Jeremy Koff, Senior Contributing Editor, Neurotech Reports, Moderator
Renee Ryan, CEO, Cala Health
Robin Davies., Chief Business Officer, MagstimEGI
Marom Bikson, Ph.D., Professor of Biomedical Engineering, City College of New York
Despite the near demise of the TENS industry, a host of new vendors have introduced noninvasive neuromodulation devices for treating a wide range of neurological disorders. In this session, we'll explore the status of invasive vs. noninvasive therapies in a number of markets.
|
11:15-12:00 |
Being BCI: The Race to Build the Perfect Brain Computer Interface
James Cavuoto, Editor and Publisher, Neurotech Reports, Moderator
Vanessa Tolosa, Ph.D., Principal Consultant, Mavato Engineering
Razi Haque, Ph.D., Implantable Microsystems Group Lead, Lawrence Livermore National Laboratory
Marcus Gerhardt, CEO, Blackrock Microsystems
In recent years, a number of startup firms and research teams have made considerable progress toward building a BCI platform that will transform neuroprosthetics and human-machine interaction. In this session, we'll look at the most signicant efforts and explore what that protends for the future. |
12:00-1:30 |
Luncheon, Sponsored by Cirtec Medical
Presentation of 2020 Gold Electrode Awards |
1:30-3:00 |
Neurotechnology Entrepreneur Panel
James Cavuoto, Editor, Neurotech Reports, Moderator
Nick Halper, Ph.D., Braingrade
Victor Pikov, Ph.D., President and CEO, Medipace
Tim Marjenin, Vice President, Neurology Regulatory Affairs, MCRA
Emil Hewage, Founder and Director, BIOS
This session features presentations from CEOs and executives of several neurotechnology start-up firms and more established technology ventures. Each executive will present an overview of their firm's technology and markets. |
3:00-3:30 |
Refreshment Break |
3:30-4:15 |
Conquering Paralysis: Neurotech Takes a Bold Step Forward
Jennifer French, Senior Contributing Editor, Neurotech Reports, Moderator
Dave Marver, CEO, GTX Medical
Parag Gad, Ph.D., CEO, SpineX
Ranu Jung, Ph.D., Professor & Chair, Department of Biomedical Engineering, Florida International University
Several new commercial firms and research instituions have made headlines recently with new neurostimulation therapies that restore function to people paralyzed by spinal cord injury and other disabilities. In this session, we'll examine the commercial market potential and explore related technologies that could complement neurostimulation approaches. |
4:15-5:00 |
Neurotech in 2025: The Shape of the Industry Five Years Down the Road
James Cavuoto, Editor and Publisher, Neurotech Reports, Moderator
Philip Sabes, Ph.D., Professor Emeritus, UCSF
Brian Pepin, CEO, Rune Labs
Stanton Rowe, CEO, NXT Biomedical
A confluence of technological and market factors is likely to trasnform the neuromodulation industry in the years ahead. In this closing session, a panel of experts will prognosticate on the potential impact of factors such as new medtech giants entering the market, wholesale changes in reimbursement policies brought on by a new administration, and increasing globalization of research and commercialization. |
5:00-7:00 |
Cocktail Reception, Sponsored by MST |
|
|
